Mizuho Securities analyst Vamil Divan maintained a Buy rating on Eli Lilly (NYSE:LLY) & Co. on Wednesday, setting a price target of $228, which is approximately 13.03% above the present share price of $201.71.
Divan expects Eli Lilly & Co. to post earnings per share (EPS) of $2.21 for the first quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Eli Lilly & Co, with an average price target of $218.1.
The analysts price targets range from a high of $256 to a low of $170.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $7.44 billion and a net profit of $2.33 billion. The company's market cap is $192.95 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of 0.0% and a 47.52% success rate.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.